Alta Biopharma Management Iii Llc - Net Worth and Insider Trading

Alta Biopharma Management Iii Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Alta Biopharma Management Iii Llc owns 7 companies in total, including Cara Therapeutics Inc (CARA) , Aegerion Pharmaceuticals Inc (AEGR) , and Sunesis Pharmaceuticals Inc (SNSS) among others .

Click here to see the complete history of Alta Biopharma Management Iii Llc’s form 4 insider trades.

Insider Ownership Summary of Alta Biopharma Management Iii Llc

Ticker	Comapny	Transaction Date	Type of Owner
CARA	Cara Therapeutics Inc	2014-01-30	10 percent owner
AEGR	Aegerion Pharmaceuticals Inc	2012-10-15	10 percent owner
SNSS	Sunesis Pharmaceuticals Inc	2010-06-30	other: Former 10% Owner
		2008-08-29	10 percent owner
		2009-09-03	other: No longer 10% owner
		2007-05-07	10 percent owner
		2009-04-03	10 percent owner

Alta Biopharma Management Iii Llc Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Alta Biopharma Management Iii Llc Ownership Network

Ownership Network List of Alta Biopharma Management Iii Llc

No Data

Ownership Network Relation of Alta Biopharma Management Iii Llc

Alta Biopharma Management Iii Llc Owned Company Details

What does Cara Therapeutics Inc do?

Who are the key executives at Cara Therapeutics Inc?

Alta Biopharma Management Iii Llc is the 10 percent owner of Cara Therapeutics Inc. Other key executives at Cara Therapeutics Inc include Chief Medical Officer Joana Goncalves , Sec'y; Chief Compliance & G.C. Scott Terrillion , and VP-Research & Development Menzaghi Frederique Ph.d. .

Cara Therapeutics Inc (CARA) Insider Trades Summary

Over the past 18 months, Alta Biopharma Management Iii Llc made no insider transaction in Cara Therapeutics Inc (CARA). Other recent insider transactions involving Cara Therapeutics Inc (CARA) include a net sale of 60,412 shares made by Christopher Posner , a net sale of 5,476 shares made by Joana Goncalves , and a net sale of 5,236 shares made by Scott Terrillion .

In summary, during the past 3 months, insiders sold 3,668 shares of Cara Therapeutics Inc (CARA) in total and bought 0 shares, with a net sale of 3,668 shares. During the past 18 months, 74,117 shares of Cara Therapeutics Inc (CARA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 74,117 shares.

Cara Therapeutics Inc (CARA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cara Therapeutics Inc Insider Transactions

No Available Data

What does Aegerion Pharmaceuticals Inc do?

Who are the key executives at Aegerion Pharmaceuticals Inc?

Alta Biopharma Management Iii Llc is the 10 percent owner of Aegerion Pharmaceuticals Inc. Other key executives at Aegerion Pharmaceuticals Inc include director & Chief Executive Officer Mary T Szela , other: See Remarks Gregory D Perry , and General Counsel and Secretary Benjamin Harshbarger .

Aegerion Pharmaceuticals Inc (AEGR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aegerion Pharmaceuticals Inc (AEGR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aegerion Pharmaceuticals Inc (AEGR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aegerion Pharmaceuticals Inc (AEGR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aegerion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sunesis Pharmaceuticals Inc do?

Who are the key executives at Sunesis Pharmaceuticals Inc?

Alta Biopharma Management Iii Llc is the other: Former 10% Owner of Sunesis Pharmaceuticals Inc. Other key executives at Sunesis Pharmaceuticals Inc include director & See Remarks Dayton Misfeldt , VP & Finance Tina Gullotta , and See Remarks William P. Quinn .

Sunesis Pharmaceuticals Inc (SNSS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sunesis Pharmaceuticals Inc (SNSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sunesis Pharmaceuticals Inc (SNSS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sunesis Pharmaceuticals Inc (SNSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sunesis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Molecular Templates Inc do?

Who are the key executives at Molecular Templates Inc?

Alta Biopharma Management Iii Llc is the 10 percent owner of Molecular Templates Inc. Other key executives at Molecular Templates Inc include 10 percent owner Biotech Target N V , Chief Medical Officer Maurizio Voi , and CFO & Treasurer Sean Mclennan .

Molecular Templates Inc (MTEM) Insider Trades Summary

Over the past 18 months, Alta Biopharma Management Iii Llc made no insider transaction in Molecular Templates Inc (MTEM). Other recent insider transactions involving Molecular Templates Inc (MTEM) include a net purchase of 4,505,319 shares made by Biotech Target N V ,

In summary, during the past 3 months, insiders sold 0 shares of Molecular Templates Inc (MTEM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Molecular Templates Inc (MTEM) were sold and 533,688 shares were bought by its insiders, resulting in a net purchase of 533,688 shares.

Molecular Templates Inc (MTEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Molecular Templates Inc Insider Transactions

No Available Data

What does Raptor Pharmaceutical Corp do?

Who are the key executives at Raptor Pharmaceutical Corp?

Alta Biopharma Management Iii Llc is the other: No longer 10% owner of Raptor Pharmaceutical Corp. Other key executives at Raptor Pharmaceutical Corp include Chief Medical Officer Krishna R Polu , Chief Financial Officer Michael P Smith , and Chief Commercial Officer David Happel .

Raptor Pharmaceutical Corp (RPTP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Raptor Pharmaceutical Corp (RPTP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Raptor Pharmaceutical Corp (RPTP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Raptor Pharmaceutical Corp (RPTP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Raptor Pharmaceutical Corp Insider Transactions

No Available Data

What does NeurogesX Inc do?

Who are the key executives at NeurogesX Inc?

Alta Biopharma Management Iii Llc is the 10 percent owner of NeurogesX Inc. Other key executives at NeurogesX Inc include President and CEO Ron Martell , Exec. V.P. & COO & CFO Stephen F Ghiglieri , and director & 10 percent owner Robert Nelsen .

NeurogesX Inc (NGSX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NeurogesX Inc (NGSX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NeurogesX Inc (NGSX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NeurogesX Inc (NGSX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NeurogesX Inc Insider Transactions

No Available Data

What does Viracta Therapeutics Inc do?

Who are the key executives at Viracta Therapeutics Inc?

Alta Biopharma Management Iii Llc is the 10 percent owner of Viracta Therapeutics Inc. Other key executives at Viracta Therapeutics Inc include Chief Executive Officer Daniel R. Chevallard , director & President and CEO Mark Rothera , and Chief Medical Officer Darrel P. Cohen .

Viracta Therapeutics Inc (VIRX) Insider Trades Summary

Over the past 18 months, Alta Biopharma Management Iii Llc made no insider transaction in Viracta Therapeutics Inc (VIRX). Other recent insider transactions involving Viracta Therapeutics Inc (VIRX) include a net sale of 14,272 shares made by Daniel R. Chevallard , and a net purchase of 100,000 shares made by Mark Rothera .

In summary, during the past 3 months, insiders sold 0 shares of Viracta Therapeutics Inc (VIRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 14,272 shares of Viracta Therapeutics Inc (VIRX) were sold and 100,000 shares were bought by its insiders, resulting in a net purchase of 85,728 shares.

Viracta Therapeutics Inc (VIRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viracta Therapeutics Inc Insider Transactions

No Available Data

Alta Biopharma Management Iii Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Alta Biopharma Management Iii Llc. You might contact Alta Biopharma Management Iii Llc via mailing address: One Embarcadero Center, Suite 3700, San Francisco Ca 94111.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.